Also trades as: 0M40.L (LSE) · $vol 0M
ZYNE NASDAQ
Zynerba Pharmaceuticals, Inc.
1W: +1.6%
1M: -3.7%
3M: +271.4%
1Y: +90.9%
3Y: -64.0%
5Y: -81.4%
$1.30
Last traded 2023-10-13 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$70.1M
52W Range0.25-1.4
Volume861,742
Avg Volume1,147,454
Beta1.19
Dividend—
Analyst Ratings
Company Info
CEOArmando Anido MBA
Employees25
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2015-08-05
Websitezynerba.com
80 West Lancaster Avenue
Devon, PA 19333
US
Devon, PA 19333
US
484 581 7505
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Jones Kenneth T | A-Award | 30,000 | — | 2023-10-10 |
| Jones Kenneth T | U-Tender | 40,520 | $1.11 | 2023-10-10 |
| Jones Kenneth T | U-Tender | 75,000 | — | 2023-10-10 |
| Jones Kenneth T | D-Return | 21,250 | $2.41 | 2023-10-10 |
| Stephenson Pamela | U-Tender | 27,954 | $1.11 | 2023-10-10 |